Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 2Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Ifosfamide 3Etoposide 3Thiotepa 2Stem Cell Transplantation 2Radiotherapy 2Melphalan 2Irinotecan 2Filgrastim 2thymoglobulin 1temsirolimus 1sargramostim 1robatumumab 1omburtamab I-131 1fludarabine phosphate 1etoposide phosphate 1Valproic Acid 1Temozolomide 1Tacrolimus 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Neoadjuvant Therapy 1Mycophenolic Acid 1Microarray Analysis 1Mesna 1Immunohistochemistry 1Immunoenzyme Techniques 1Granulocyte Colony-Stimulating Factor 1FANG vaccine 1Doxorubicin 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroectodermal Tumors, Primitive, Peripheral × robatumumab × Clear all
NCT00617890 2018-08-23

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

Merck Sharp & Dohme LLC

Phase 2 Terminated
219 enrolled 13 charts
Sarcoma

Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡